HCT116 Xenograft Rat Model Service for Colon Cancer

The HCT116 xenograft rat model offers a powerful and translationally relevant platform for dissecting colorectal carcinoma pathophysiology and evaluating novel therapeutic candidates in a physiologically intact setting. At Alfa Cytology, we specialize in the design, execution, and analytical characterization of HCT116-based rat xenograft studies—delivering reproducible tumor data, comprehensive pharmacodynamic readouts, and histopathological endpoints that empower your preclinical oncology program from lead optimization through candidate selection.

Overview of HCT116 Xenograft Rat Model for Colon Cancer

HCT116 is a human colorectal carcinoma cell line originally isolated in 1979 from the epithelial tumor tissue of a male patient with colon cancer. Genetically, this line is defined by microsatellite instability-high (MSI-H) status, an oncogenic KRAS mutation, and alterations in PIK3CA, CTNNB1, and CDKN2A—a molecular signature that closely mirrors a subset of aggressive, poorly differentiated colorectal cancers in the clinic. When engrafted into immunodeficient rats, HCT116 cells demonstrate robust tumorigenicity, with palpable tumors typically emerging within 7–10 days following subcutaneous or orthotopic inoculation. The rat host offers distinct practical advantages over murine systems, including a larger blood volume that supports serial pharmacokinetic sampling, superior imaging resolution for longitudinal tumor tracking, and anatomical dimensions that facilitate precise surgical orthotopic implantation into the cecal wall or colonic submucosa.

Fig 1. Construction strategies for four classic tumor models. (Huang, Qin, et al., 2025)

Beyond primary tumor formation, HCT116 rat xenografts faithfully recapitulate the metastatic cascade characteristic of human colorectal carcinoma. Orthotopic models established via cecal implantation exhibit local invasion into the colonic wall, peritoneal dissemination, and spontaneous distant colonization of the liver and lungs—fulfilling the rate-limiting steps of metastasis that subcutaneous models cannot replicate. Researchers leverage this system to interrogate anti-proliferative efficacy, anti-metastatic potential, DNA damage response modulation, and combination regimen scheduling. The model's well-characterized genetic background also makes it particularly suited for evaluating targeted agents directed against RAS-driven signaling, PI3K/AKT pathway inhibitors, and immunotherapeutic strategies in the MSI-H context.

Cell Line Information: HCT116

HCT116 ranks among the most thoroughly annotated and widely deployed colorectal cancer cell lines in oncology research. The table below consolidates its essential biological, genetic, and culture characteristics pertinent to xenograft model development.

Our Services

Alfa Cytology offers comprehensive HCT116 xenograft rat model services engineered to meet the exacting standards of contemporary preclinical colorectal cancer research. From cell line authentication and immunodeficient rat procurement through orthotopic surgical implantation, longitudinal tumor monitoring, and multi-modal endpoint analysis, our team ensures every study is executed with methodological rigor and complete traceability. Whether your objective is to benchmark a cytotoxic agent, evaluate a targeted small molecule against RAS-mutant disease, or dissect combination therapy dynamics, we provide the infrastructure and scientific depth to generate decision-ready data.

Workflow of HCT116 Xenograft Rat Model Construction

Establishing a reliable HCT116 xenograft rat model requires disciplined execution across cell preparation, animal handling, surgical technique, and post-operative surveillance. The following workflow delineates each critical phase to ensure consistent engraftment, predictable tumor kinetics, and high-quality endpoint data.

1. Cell Expansion and Pre-Inoculation QC: HCT116 cells are maintained in McCoy's 5A or RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified 5% CO₂ incubator. Prior to in vivo use, cells undergo STR authentication to confirm identity, mycoplasma PCR testing to rule out contamination, and passage-number logging (ideally below P20) to preserve genetic stability and tumorigenic competence.
2. Recipient Rat Preparation and Randomization: Immunodeficient rats—commonly athymic nude (RNU) or severely immunocompromised strains—are acclimatized for a minimum of five days under specific pathogen-free (SPF) conditions. Baseline body weights, clinical observations, and hematological parameters are documented. Animals are randomized into cohorts stratified by body mass to minimize inter-group variability.
3. Cell Harvest and Formulation: At 70–80% confluence, cells are detached with 0.05% trypsin-EDTA, washed in phosphate-buffered saline, and enumerated using an automated cell counter. Viability must exceed 95% as determined by trypan blue exclusion. Cells are resuspended at a concentration of 1–5 × 10⁶ cells/mL in ice-cold PBS or serum-free medium. For enhanced tumor take, the suspension may be admixed 1:1 with Matrigel or a synthetic basement membrane substitute.
4. Tumor Cell Inoculation: For subcutaneous models, 100–200 µL of cell suspension (containing 1–5 × 10⁶ viable cells) is injected into the flank subcutaneous space using a 25-gauge needle. For orthotopic models, a mini-laparotomy exposes the cecum, and 2–5 × 10⁶ cells in 20–50 µL are injected into the cecal submucosa or serosal layer under direct visualization. The abdominal wall is closed in layers, and post-operative analgesia is administered per institutional guidelines.
5. In-Life Monitoring and Tumor Measurement: Following implantation, animals are monitored daily for clinical signs, body weight, and wound integrity. Tumor dimensions are measured with digital calipers two to three times per week, with volumes calculated using the modified ellipsoid formula: Volume = (length × width²) × 0.5. Concurrent body weight tracking and clinical scoring enable early detection of treatment-related toxicity or unexpected morbidity.
6. Dosing and Pharmacodynamic Sampling: Once tumors reach the target volume (typically 100–200 mm³), animals are randomized into vehicle control and treatment groups. Test compounds are administered via oral gavage, intravenous bolus, intraperitoneal injection, or continuous infusion according to the study design. Serial blood collections (up to 300 µL per draw in rats) support pharmacokinetic profiling without compromising animal welfare. Tumor biopsies may be harvested at interim time points for mechanistic biomarker analysis.
7. Necropsy and Comprehensive Endpoint Analysis: At study termination, animals are humanely euthanized under IACUC-approved protocols. Primary tumors are excised, weighed, photographed, and allocated for histopathology, molecular profiling, and biomarker analysis. Distant organs—including liver, lung, lymph nodes, and peritoneum—are meticulously examined for metastatic deposits via hematoxylin and eosin staining, immunohistochemistry (e.g., Ki-67, CD31, cleaved caspase-3), and quantitative PCR. Blood and plasma samples are analyzed for circulating tumor markers, cytokine profiles, and drug exposure metrics.

Fig 2. HCT116 Xenograft Rat Model construction workflow.

Case Study-HCT116 Xenograft Rat Model Development

In a recent preclinical investigation, male athymic nude rats received orthotopic implantation of HCT116 cells into the cecal wall, achieving a 100% tumor engraftment rate with palpable abdominal masses detectable by ultrasound within 10–14 days. Tumors demonstrated aggressive local invasion into the colonic muscularis propria and serosa, with 50–60% of animals developing macroscopic liver metastases and 40–45% exhibiting pulmonary micrometastases by study endpoint. A parallel treatment cohort received a combination regimen comprising a standard cytotoxic agent and a targeted PI3K pathway inhibitor, resulting in statistically significant tumor growth inhibition relative to vehicle controls, alongside reduced metastatic burden in the liver and diminished Ki-67 proliferation index within residual tumor tissue. These outcomes highlight the translational value of the HCT116 rat xenograft platform for evaluating both primary tumor response and anti-metastatic efficacy in the colorectal cancer setting.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HCT116 xenograft rat model studies means gaining access to a scientifically driven CRO where operational precision meets deep oncology expertise. Our integrated approach minimizes hand-off delays, preserves sample integrity, and delivers data packages that withstand both internal peer review and external regulatory scrutiny.

• Rigorously Qualified Models — Every HCT116 rat xenograft batch is validated for tumor take rate, growth kinetics, and positive-control responsiveness prior to client study initiation.
• Advanced Surgical Capabilities — Our veterinary team performs mini-laparotomy-based cecal orthotopic implantation with high reproducibility, enabling metastasis-competent models that subcutaneous systems cannot match.
• End-to-End Analytical Integration — In-house histopathology, IHC, flow cytometry, qPCR, and multiplex cytokine analysis eliminate external vendor dependencies and accelerate turnaround times.
• Bespoke Study Architectures — We accommodate custom dosing schedules, multi-arm combination designs, various administration routes, and specialized imaging endpoints aligned with your compound's mechanism of action.
• Regulatory-Compliant Operations — All protocols are IACUC-approved, with real-time data capture, chain-of-custody documentation, and audited final reports suitable for IND-enabling packages.
• PhD-Led Scientific Partnership — Each project is stewarded by a dedicated scientific lead who provides weekly progress briefings, troubleshoots emergent technical issues, and ensures seamless alignment with your development milestones.

Contact Us

Interested in leveraging a validated HCT116 xenograft rat model to advance your colorectal cancer pipeline? Contact us now to discuss your study parameters, compound profile, and desired endpoints. Our preclinical oncology team will work closely with you to architect a tailored experimental strategy that generates robust, publication-ready data and moves your therapeutic candidate closer to IND submission. Whether you require a straightforward subcutaneous efficacy screen or a sophisticated orthotopic metastasis model with longitudinal imaging, Alfa Cytology is equipped to deliver.

For research use only. Not intended for any clinical use.